$TENX News

Tenax Therapeutics (TENX) Stock Fair Value Falls After Cautious Analyst Calls On LEVEL Data

Tenax Therapeutics Temporarily Pauses Enrollment In LEVEL-2 Trial Of TNX-103 To Amend Criteria; Requests FDA Meeting

Tenax Therapeutics, Inc. (TENX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Guggenheim Downgrades Tenax Therapeutics to Neutral

Reported Earlier, Tenax Reports New Phase 3 Data Supporting TNX-103 In Pulmonary Hypertension Patients

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Tenax Therapeutics’ stock crashes on Phase III trial failure

Guggenheim Maintains Buy on Tenax Therapeutics, Lowers Price Target to $4

Evercore ISI Group Downgrades Tenax Therapeutics to In-Line, Lowers Price Target to $5

Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients - Slideshow

William Blair Downgrades Tenax Therapeutics to Market Perform

Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103

Why Did TENX Stock Crash 89% Today?

Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints